# BioVersys

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bioversys

- Industry: Biotechnology
- Headquarters: Basel, Switzerland
- Website: www.bioversys.com
- Total disclosed funding: $33M
- Latest round: Series C (Jan 5, 2023)
- Investors on record: 7

## About

Based in Switzerland, BioVersys AG functions as a biotechnology firm dedicated to developing innovative solutions to combat antimicrobial resistance through advanced pharmaceuticals.BioVersys AG, founded in 2010 by founder and CEO Marc Gitzinger in Basel, Switzerland, focuses on addressing antimicrobial resistance through novel pharmaceutical developments. In November 2025, BioVersys AG raised SGD 22 million in venture funding from investor Wellcome Trust. BioVersys specializes in combating antimicrobial resistance (AMR) through the development of innovative pharmaceutical solutions. Their core offerings include novel antibiotic candidates such as BV100, Alpibectir, BV200, and BV500, each designed to target specific drug-resistant infections. BV100 addresses serious hospital infections caused by Acinetobacter baumannii, while Alpibectir focuses on multidrug-resistant tuberculosis (MDR-TB) and TB meningitis. These products possess unique modes of action, aiming to overcome existing antibiotics' limitations and restore treatment efficacy. BioVersys primarily serves healthcare providers, hospitals, and public health organizations, targeting markets in Europe, North America, and Asia, where AMR presents significant challenges to patient care.The revenue model of BioVersys is built around partnerships with healthcare institutions and pharmaceutical companies, leveraging collaborative agreements to facilitate the development and commercialization of their products. This includes direct B2B transactions where hospitals and healthcare providers purchase their antibiotic innovations to enhance treatment options for resistant infections. Additionally, BioVersys engages in strategic collaborations that may involve milestone payments or royalties based on the commercial success of their drug candidates. Specific pricing structures for their products are established during negotiations with healthcare partners, reflecting the critical nature of these therapeutics in addressing serious infectious diseases. The company’s financial performance is closely tied to the progress of its clinical trials and the successful launch of its drug candidates.to conduct a Phase 2b trial of BV100 via ADVANCE-ID, expand treatment arms, enroll CRAB patients, and generate pivotal data for Phase 3 regulatory submissions.

## Funding rounds

- Series C, Jan 5, 2023, $9M — AMR Action Fund
- Series B, Sep 1, 2020, $21M — European Union, CARB-X
- Seed, Mar 31, 2011, $2.8M — EVA, BioValley Business Angels Club, GoBeyond
- Seed, May 27, 2009, $0.1M — Venture Kick

## Investors

- Venture Kick (https://capitalatlas.ai/funds/venture-kick) — Seed
- EVA (https://capitalatlas.ai/funds/eva) — Seed
- BioValley Business Angels Club — Seed
- GoBeyond — Seed
- European Union — Series B
- CARB-X (https://capitalatlas.ai/funds/carb-x) — Series B
- AMR Action Fund (https://capitalatlas.ai/funds/amr-action-fund) — Series C